export default function ThymosinBeta4OverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Thymosin Beta-4 is the naturally occurring protein your body produces — a 43-amino acid molecule found in virtually every cell, with roles in how cells move, how tissue heals, and how inflammation is controlled. TB-500, the compound most people in the peptide community actually use, is a synthetic fragment of this protein. The full protein has the most advanced human clinical data of any thymosin compound, but understanding the distinction between the endogenous protein and the synthetic fragment matters before making any decisions.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; Trying to Understand What TB-500 Actually Is</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I keep seeing TB-500 and TB4 used interchangeably. What&rsquo;s the actual difference, and does it matter which one I use?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The &ldquo;natural peptide your body already makes&rdquo; framing feels safer</strong><br />Thymosin Beta-4 is endogenous — your body produces it constantly as part of normal cell function. For someone cautious about introducing foreign compounds, knowing that the underlying molecule is already present in your biology provides some reassurance about the basic mechanism.</li>
          <li><strong>The healing biology is coherent and well-characterized</strong><br />Thymosin Beta-4&rsquo;s role in controlling actin — the protein that allows cells to change shape and migrate — explains why it promotes wound healing, tissue repair, and inflammation resolution. This is basic cell biology, not a speculative mechanism extrapolated from a single rat study.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">&ldquo;Natural&rdquo; does not mean safe at exogenous doses or in peptide-supplement form. TB-500 (the synthetic fragment) is what essentially all community users are actually buying and injecting — and most products labeled &ldquo;thymosin beta-4&rdquo; in the research peptide market are TB-500, not the full protein. The endogenous form is an intracellular protein; injecting it exogenously is a completely different context than its natural biology. Cancer history is a hard stop because the angiogenesis and cell migration mechanisms cannot distinguish beneficial repair from tumor-supporting activity. Net: the biology is real and interesting, but &ldquo;endogenous&rdquo; does not equal &ldquo;safe to inject.&rdquo;</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; Injury Recovery and Healing Optimization</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I have a chronic tendon issue. I&rsquo;ve looked at BPC-157 and TB-500. What does understanding the endogenous thymosin beta-4 biology tell me about which direction to go?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The actin sequestration mechanism maps well onto tendon and soft tissue repair</strong><br />Tendon repair depends on fibroblast migration to the injury site — and fibroblast migration requires dynamic actin remodeling. Thymosin Beta-4&rsquo;s role in controlling actin polymerization directly supports this cell motility process. The mechanism is relevant to the use case, not just generically &ldquo;healing.&rdquo;</li>
          <li><strong>The anti-inflammatory aspect complements the repair aspect</strong><br />Thymosin Beta-4 reduces inflammatory signaling (via NF-κB pathway modulation) while simultaneously promoting repair cell migration. That combination — turning down the inflammatory response while supporting the structural repair — is what athletes experiencing chronic overuse injuries often need.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The most rigorous human evidence for thymosin beta-4 is in cardiac repair and dry eye disease — not tendon or musculoskeletal injury. The athletic use case is an extrapolation from the mechanism and from animal model tissue repair studies. TB-500 (the fragment) is what you&rsquo;re almost certainly accessing if you go through research peptide suppliers — the full protein page covers the clinical distinction in more detail. BPC-157 and thymosin beta-4 fragment both appear in injury contexts and work through different mechanisms; comparing them is a legitimate question answered elsewhere on this site. Cancer screening before any thymosin compound remains non-negotiable. Net: mechanistically well-matched to the athlete use case, but the specific evidence for musculoskeletal healing in humans is absent.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; Actin Biology and Regenerative Mechanisms</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;Thymosin Beta-4 is one of the most abundant proteins in mammalian cells. The cardiac repair trial data is interesting. How does understanding the endogenous form help me evaluate TB-500 and the full protein compound?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Actin regulation is fundamental to cell biology in ways most peptides don&rsquo;t touch</strong><br />Thymosin Beta-4 is one of the primary intracellular regulators of the actin cytoskeleton — it sequesters monomeric actin and controls the pool available for polymerization. This touches everything from cell division and migration to immune cell function and wound healing. Modulating this at a systems level is a genuinely different category of intervention than receptor-targeted compounds.</li>
          <li><strong>The fragment-to-full-protein distinction has real mechanistic implications</strong><br />TB-500 retains the actin-sequestering region but lacks the integrin-linked kinase activation domain of the full protein. Understanding this distinction helps evaluate what the clinical trial evidence (full protein, cardiac context) does and doesn&rsquo;t tell you about the fragment (community healing context). The translation gap is real and worth mapping carefully.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The endogenous form is intracellular — it functions inside cells as part of normal cytoskeletal dynamics. Exogenous administration of the peptide operates through different receptor-mediated and paracrine pathways. The extrapolation from intracellular biology to injectable peptide pharmacology involves assumptions that are not fully characterized. The cardiac repair pilot data is promising but small, and full clinical development has been slow — the compound has not progressed to Phase 3 approval in any indication as of early 2026. Net: the deepest mechanistic picture of this compound family comes from studying the endogenous form, but it requires careful mental separation of intracellular biology from exogenous peptide pharmacology.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Thymosin Beta-4 (endogenous) is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>The same compound as TB-500 — the synthetic fragment has a subset of the full protein&rsquo;s activity</li>
              <li>Proven to work when injected for the use cases athletes care about — the human evidence is cardiac and ophthalmic, not musculoskeletal</li>
              <li>Safe because it&rsquo;s &ldquo;natural&rdquo; — endogenous function is intracellular; injectable exogenous administration is a different context</li>
              <li>Accessible in authentic form through gray-market suppliers — most products sold as thymosin beta-4 are actually TB-500</li>
              <li>Safe for people with cancer history — the angiogenesis mechanism is a shared hard stop for both the full protein and TB-500</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>One of the most abundant proteins in mammalian cells — deeply embedded in fundamental cell biology</li>
              <li>The actin sequestration mechanism is mechanistically distinct from angiogenesis-focused repair compounds like BPC-157</li>
              <li>The full protein has the most advanced human clinical trial data of any thymosin compound (Phase 2 cardiac repair)</li>
              <li>Understanding the endogenous form correctly frames the TB-500 fragment evidence and the translation gap between them</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
